Home>Topics>Companies>Boston Scientific

Boston Scientific BSX

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Johnson & Johnson's $7.2 billion claim against Boston Scientific now with U.S. judge

      Headlines

      Wed, 21 Jan 2015

      NEW YORK (Reuters) - For more than eight years, Johnson & Johnson has pursued billions of dollars in damages against Boston Scientific Corp after the latter won a controversial – and ultimately ill-fated – bidding war for device maker Guidant.

    2. J&J's $7.2 bln claim against Boston Scientific now with U.S. judge

      Headlines

      Wed, 21 Jan 2015

      NEW YORK, Jan 21 (Reuters) - For more than eight years, Johnson & Johnson has pursued billions of dollars in damages against Boston Scientific Corp after the latter won a controversial - and ultimately ill-fated - bidding war for device maker Guidant.

    3. Acquisition of Volcano Enhances Narrow-Moat Philips' Position in Medical Imaging

      Commentary

      Wed, 17 Dec 2014

      and perform the minimally invasive treatment. Although we have seen increasing competition in IVUS (Terumo and Boston Scientific launched products recently) and FFR (Acist/Medtronic entering the market), we like Volcano's broad product

    4. From Barron’s, October 27, 2014 (Part 2

      Commentary

      Sat, 25 Oct 2014

      companies will continue to benefit from it [ THC, WCG ]. The medical-device tax may be repealed and that will benefit BSX , BAC . Pg 16-17 : 25 euro-zone banks are expected to fail the ECB stress tests to be announced on Sunday [Oct 26

    5. From Barron’s, October 27, 2014 (Part 1)

      Commentary

      Sat, 25 Oct 2014

      companies will continue to benefit from it [ THC, WCG ]. The medical-device tax may be repealed and that will benefit BSX , BAC . Pg 16-17 : 25 euro-zone banks are expected to fail the ECB stress tests to be announced on Sunday [Oct 26

    6. Boston Scientific's Strong 3Q Fueled by Stellar Stent Performance

      Commentary

      Wed, 22 Oct 2014

      Boston Scientific reported strong third-quarter performance, and we have increased our fair value estimate to $12 per share from $10 after incorporating

    7. Abbott Posts Solid 3Q, but Vascular Devices Continues to Struggle

      Commentary

      Wed, 22 Oct 2014

      for several years thanks to more clinical evidence suggesting overstated clinical benefits, competitors such as Boston Scientific and Medtronic have been better able to navigate choppy waters with new innovation. Indeed, Boston's third-quarter

    8. Edwards Lifesciences Posts Strong 2Q on New Launches; We've Raised Our Fair Value Estimate

      Commentary

      Wed, 30 Jul 2014

      had cautiously anticipated rising competition now that Medtronic has entered the U.S. and St. Jude Medical and Boston Scientific have launched in Europe, Edwards showed its own strength in both markets with its rollout of Sapien XT and Sapien

    9. Boston Scientific Exceeds Our Expectations in the Second Quarter

      Commentary

      Thu, 24 Jul 2014

      Boston Scientific released second-quarter performance that exceeded our expectations, and we plan to modestly increase our fair value estimate

    10. Tides Turn for These Orthopedic Firms

      Headlines

      Mon, 30 Jun 2014

      switching costs lower in cardiac rhythm management devices, the three CRM makers--Medtronic, St. Jude Medical, and Boston Scientific --derive much of their moatiness from efficient scale and operate in a rational oligopoly. In this situation

    « Prev12345Next »
    Content Partners